GR-GAL4 Luciferase Reporter HEK293 Cell Line (Glucocorticoid Receptor Pathway)
The GR-GAL4 Luciferase Reporter HEK293 Cell Line is a HEK293 cell line expressing firefly luciferase under the control of glucocorticoid receptor ligand binding domain fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR). This fusion construct activates firefly luciferase expression via control of a multimerized GAL4 upstream activation sequence (UAS). This system allows specific detection of glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual transcriptional targets and has low cross-reactivity with other nuclear receptor pathways. This cell line has been validated by stimulation with dexamethasone and treatment with mifepristone, an inhibitor of the glucocorticoid signaling pathway.
Interested in screening and profiling inhibitors or activators of glucocorticoid receptor without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 1 | BPS Bioscience #60187 |
Growth Medium 1G | BPS Bioscience #79544 |
Materials Required for Cellular Assay
Name | Ordering Information |
Dexamethasone | Sigma #D4902 |
Mifepristone/RU-486 | Sigma #M8046 |
96-well tissue culture treated white clear-bottom assay plate | Corning #3610 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
The glucocorticoid signaling pathway plays an important role in development, fluid homeostasis, cognition, immune response, and metabolism. Glucocorticoids are a class of steroid hormones that bind to the glucocorticoid receptor, causing it to translocate to the nucleus. Upon translocation, the receptor can regulate the transcription of a large number of genes by binding to the GRE (glucocorticoid response elements), including those that regulate glucose metabolism and inflammatory responses. The complex receptor:ligand results in up-regulation of expression of anti-inflammatory proteins (transactivation), and downregulates the expression of pro-inflammatory ones by inhibiting the translocation of the transcription factors required for their expression to the nucleus (transrepression). Glucocorticoids are used in the treatment of diseases linked to over stimulation of the immune system, for example in allergies, asthma, autoimmune diseases, and sepsis. They have also been used in cancer therapy at high doses, as they inhibit lymphocyte proliferation in lymphoma and leukemia, and organ transplant. Long term use of glucocorticoids can result in cataract, hypertension, type 2 diabetes, among other side effects. An in depth understanding of the glucocorticoid signaling pathway will lead to better tailored treatment options.
Paguio A, et al., 2010 Curr Chem Genomics. 4: 43-49.